Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339963 · ClinicalTrials.gov registry record
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
A clinical trial of Multiple Myeloma and Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 1,340
- Enrollment target
- 1
- Study location
NCT00339963 is a study of Multiple Myeloma and Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,340 participants, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (146% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00339963, a study of Multiple Myeloma and Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 1,340 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use genomics-based technology, such as DNA microarrays, to more precisely diagnose subsets of lymphoma, leukemia and multiple myeloma patients. There have been many attempts to classify lymphoid cancers in ways that will be useful for clinical diagnosis and treatment. Although broad diagnostic categories have been reliably defined, patients within each category have distinct clinical courses, suggesting that these classifications could be further divided into molecular (genetic) subtypes. For example, 40 percent of patients with diffuse large B-cell lymphoma achieve long-term disease remissions following combination chemotherapy and are apparently cured, whereas the remaining 60 percent die from the disease. Similarly, some patients with follicular lymphoma develop aggressive disease within a few years of diagnosis, while others have stable disease over 10 to 20 years. Although the distinctions in clinical course of these diseases are recognized, there are no studies to determine the molecular (genetic) basis for this variability. This study will try to define new molecular diagnostic categories in these diseases and correlate them with clinical features, including treatment response, disease remission and overall survival following chemotherapy. This retrospective study will use clinical data and tissue samples from participating centers in the Lymphoma/Leukemia Molecular Profiling Project LLMPP). New patients will not be recruited for this study. Biopsy materials, including fresh frozen or OTC-embedded lymphoma biopsy material, viably frozen samples of peripheral blood cells from leukemia patients, and viably frozen samples of bone marrow aspirates from multiple myeloma patients will be collected from pathologists participating in the LLMPP. RNA and genomic DNA will be extracted from the tumor samples. A variety of technologies will be used to characterize the genome of the cancer cells, including lymphochip microarrays for array-based comparativ
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,340 participants |
| Start Date | 2001-11-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00339963
The ClinicalTrials.gov registry entry for NCT00339963 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,340 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (146% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT00339963 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00339963 about?
NCT00339963 is a clinical study titled "Genome Expression in Lymphoma, Leukemia and Multiple Myeloma". This study will use genomics-based technology, such as DNA microarrays, to more precisely diagnose subsets of lymphoma, leukemia and multiple myeloma patients. There have been many attempts to classify lymphoid cancers in ways that will be useful for clinical diagnosis and treatment. Although broad ...
What is the current status of trial NCT00339963?
This trial is currently completed. The enrollment target is 1,340 participants. The study started on 2001-11-09.
What conditions does trial NCT00339963 study?
This clinical trial studies the following conditions: Multiple Myeloma, Leukemia, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin.
Who is sponsoring clinical trial NCT00339963?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00339963 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.